// App-Quantinova.ai

TPS9606 : Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).

Researchers

Presenter

  • Elisa A. Rozeman

Principal Investigators

  • Alexander Christopher Jonathan Van Akkooi

  • Alexander M. Menzies

  • Myles Smith

  • Richard A. Scolyer

  • Loes M. Pronk

  • Maria Gonzales

  • Christoph Hoeller

  • Johan Hansson

  • James M. G. Larkin

  • Georgina V. Long

  • Christian U. Blank

Medical Centers

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Melanoma Institute Australia, North Sydney, Australia

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Royal Prince Alfred Hospital/Melanoma Institute Australia/University of Sydney, Sydney, Australia

  • Melanoma Institute Australia, North Sydney, Australia

  • Medical University of Vienna, Vienna, Austria

  • Department of Oncology and Pathology, Karolinska Institutet and Department of Oncology, Karolinska University Hospital, Stockholm, Sweden

  • The Royal Marsden Hospital, London, United Kingdom

  • Melanoma Institute Australia, the University of Sydney, Mater Hospital, and Royal North Shore Hospital, Sydney, Australia

Locations

  • Austria

  • Netherlands

  • United Kingdom

  • Australia

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

Phase

  • II

Study Id's

  • NCT02977052

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved